David Blue to Serve as Chief Commercial Officer as Company Advances Product Commercialization
Paul Buckman Joins Conventus Orthopaedics as Chief Executive Officer
Conventus Orthopaedics, a company creating less invasive solutions to treat a broad range of challenging peri-articular fractures, today announced the addition of two leading industry veterans to guide the company into commercial operations and market growth. Paul Buckman has joined the company as CEO and David Blue has joined as Chief Commercial Officer.
“Conventus Orthopaedics is well prepared to commercialize a solution that we believe represents a true advance in the standard of care for treating peri-articular fractures,” said Paul Hindrichs, co-founder of Conventus. “Paul and David have long track records of success and a wealth of industry experience that will serve Conventus well at this point in its evolution. Further, Paul has a deep understanding of our business as a result of serving as a member of our Board of Directors since its inception in 2009. Adding Paul and David to our leadership team is the right move for Conventus as we transform to a commercially driven company.”
Buckman has more than 30 years of leadership experience in the medical device and medical technology industry, holding executive level positions at SentreHEART, Pathway Medical Technologies, St. Jude Medical, ev3 (co-founder), Scimed/Boston Scientific and others. He has served on the Board of Directors for SentreHEART, Sunshine Heart, Microtherapeutics, Velocimed (co-founder) and ev3. Buckman earned his master's degree in Business Administration and Finance, and a bachelor’s degree in Business Administration from Western Michigan University (Kalamazoo, Michigan).
Blue is an accomplished executive with more than 30 years of commercial experience. He has spent significant time in leadership roles at start-up companies, and previously served in senior level management positions at Zimmer, Tornier, and DePuy. He has participated in an owner and partner capacity of several orthopedic companies, including owning and running his own orthopedic distributorship. Blue received a Bachelor of Arts degree in Business Administration from Augustana College (Sioux Falls, South Dakota).
The Conventus DRS™ Implant, which received clearance by the FDA earlier this year, is designed to provide a less-invasive means for orthopedic surgeons to treat patients with distal radius fractures, returning them to normal daily activities sooner and with less pain. Conventus’ DRS technology uses a unique self-expanding implant that stabilizes the fractured fragments from within the bone. The surgical procedure requires only a two-to-three centimeter incision on the forearm and a few small incisions at the wrist. The technique reduces surgical trauma by as much as 70 percent compared to traditional plate and screw fixation techniques, and preserves soft tissues around the fracture to minimize stiffness, swelling and pain. It represents the first minimally-invasive, fragment-specific system that effectively addresses a wide range of fracture types with fixation strength equivalent to that of locking plates.
was founded by a team of medical device professionals and physicians with the sole purpose of improving patient care by creating a platform technology with less invasive solutions to a broad range of challenging peri-articular fractures. Taking its name from the Latin word for coming together or union, Conventus Orthopaedics is focused on creating less invasive solutions to fractures in and around joints. The company is dedicated to working with surgeons to improve healing and enable their patients' return to normal activity.